Author

J. R. Mallareddy

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

A. Natarajan· 2 shared A. A. de Cubas· 1 shared A. Eiken· 1 shared A. Kalluchi· 1 shared A. Krishna· 1 shared A. L. Smith· 1 shared C. R. D'Angelo· 1 shared D. A. LaBreck· 1 shared

Activity by Year

2023-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Natarajan

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Novel spirocyclic dimer, SpiD3, targets chronic lymphocytic leukemia survival pathways with potent preclinical effects

A. Eiken, A. L. Smith, S. A. Skupa, E. Schmitz, S. Rana, S. Singh, S. Kumar, J. R. Mallareddy, A. A. de Cubas, A. Krishna, A. Kalluchi, J. Rowley, C. R. D'Angelo, M. A. Lunning, R. G. Bociek, , D. ElGamal

This paper evaluates SpiD3, a novel spirocyclic dimer, showing potent anti-leukemic effects in CLL cells, including resistance to ibrutinib, by targeting NF-κB signaling and the UPR.

bioRxiv · Jan 31, 2024Cancer Biology

DHODH inhibition enhances the efficacy of immune checkpoint blockade by increasing cancer cell antigen presentation

N. J. Mullen, S. K. Shukla, R. Thakur, S. S. Kollala, D. Wang, N. Chaika, J. F. Santana, W. R. Miklavcic, D. A. LaBreck, J. R. Mallareddy, D. Price, A. Natarajan, K. Mehla, D. B. Sykes, M. A. Hollingsworth, P. K. Singh

This study shows DHODH inhibition enhances immune checkpoint blockade by increasing cancer cell antigen presentation through pyrimidine depletion and P-TEFb-mediated RNA polymerase II elongation.

bioRxiv · Apr 3, 2023Cancer Biology